Alan Wolfe
Recal Non-Faculty Academic
Bioengineering
School of Pharmacy

My work on the schistosomicidal prodrug TPT sulfonate and the repurposing of auranofin for treating lymphatic filariasis and onchocerciasis has shown promise in addressing neglected tropical diseases. Additionally, I have contributed to the understanding of drug clearance and organ extraction ratio predictions, as well as the pharmacokinetics of nevirapine in HIV-infected adults. As a Coinvestigator on a project sponsored by the Sandler Center for Drug Discovery, I have played a vital role in identifying and optimizing bioactive principles for a new, single-dose, oral drug for schistosomiasis. My commitment to advancing research in pharmacology and drug development continues to drive my contributions to the field.

• TPT sulfonate, a single, oral dose schistosomicidal prodrug: In vivo efficacy, disposition and metabolic profiling.
  International journal for parasitology. Drugs and drug resistance 2018 Wolfe AR, Neitz RJ, Burlingame M, Suzuki BM, Lim KC, Scheideler M, Nelson DL, Benet LZ, Caffrey CR
• Local delivery of hormonal therapy with silastic tubing for prevention and treatment of breast cancer.
  Scientific reports 2018 Park J, Thomas S, Zhong AY, Wolfe AR, Krings G, Terranova-Barberio M, Pawlowska N, Benet LZ, Munster PN
• The Universally Unrecognized Assumption in Predicting Drug Clearance and Organ Extraction Ratio.
  Clinical pharmacology and therapeutics 2017 Benet LZ, Liu S, Wolfe AR
• Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study.
  AIDS research and therapy 2017 Monera-Penduka TG, Maponga CC, Wolfe AR, Wiesner L, Morse GD, Nhachi CF
• Naloxonazine, an Amastigote-Specific Compound, Affects Leishmania Parasites through Modulation of Host-Encoded Functions.
  PLoS neglected tropical diseases 2016 De Muylder G, Vanhollebeke B, Caljon G, Wolfe AR, McKerrow J, Dujardin JC
• Repurposing auranofin as a lead candidate for treatment of lymphatic filariasis and onchocerciasis.
  PLoS neglected tropical diseases 2015 Bulman CA, Bidlow CM, Lustigman S, Cho-Ngwa F, Williams D, Rascón AA, Tricoche N, Samje M, Bell A, Suzuki B, Lim KC, Supakorndej N, Supakorndej P, Wolfe AR, Knudsen GM, Chen S, Wilson C, Ang KH, Arkin…
• Best single time point correlations with AUC for cyclosporine and tacrolimus in HIV-infected kidney and liver transplant recipients.
  Transplantation 2014 Frassetto LA, Tan-Tam CC, Barin B, Browne M, Wolfe AR, Stock PG, Roland M, Benet LZ
• Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients.
  Biopharmaceutics & drug disposition 2013 Frassetto L, Floren L, Barin B, Browne M, Wolfe A, Roland M, Stock P, Carlson L, Christians U, Benet L
• OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis.
  Pharmacogenetics and genomics 2013 Tamraz B, Fukushima H, Wolfe AR, Kaspera R, Totah RA, Floyd JS, Ma B, Chu C, Marciante KD, Heckbert SR, Psaty BM, Kroetz DL, Kwok PY
• CYCLOSPORINE AND TACROLIMUS PHARMACOKINETICS IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED LIVER AND KIDNEY TRANSPLANT RECIPIENTS.
  Transplantation Journal 2010 C. TanTam, L. Frassetto, B. Barin, M. Browne, A. Wolfe, P. Stock, M. Roland, L. Benet
• In vitro inhibitory effects of Hypoxis obtusa and Dicoma anomala on cyp450 enzymes and p-glycoprotein
  Afr J Pharm Pharmacol 2009 Gwaza L, Wolfe AR, Benet LZ, Guglielmo BJ, Chagwedera TE, Maponga CC, Masimirembwa CM
• Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women.
  Journal of acquired immune deficiency syndromes (1999) 2009 Gandhi M, Benet LZ, Bacchetti P, Kalinowski A, Anastos K, Wolfe AR, Young M, Cohen M, Minkoff H, Gange SJ, Greenblatt RM, Women's Interagency HIV Study
• Moringa oleifera leaf extracts inhibit 6beta-hydroxylation of testosterone by CYP3A4.
  Journal of infection in developing countries 2008 Monera TG, Wolfe AR, Maponga CC, Benet LZ, Guglielmo J
• Benzo[a]pyrene diol epoxide forms covalent adducts with deoxycytidylic acid by alkylation at both exocyclic amino N(4) and ring imino N-3 positions.
  Chemical research in toxicology 2004 Wolfe AR, Smith TJ, Meehan T
• Trans- and cis-DNA adduct concentration in epidermis from mouse and rat skin treated ex vivo with benzo[a]pyrene diol epoxide and its corresponding chlorohydrin.
  Mutation research 2001 Vock EH, Wolfe AR, Meehan T
• Branched cationic peptides for gene delivery: role of type and number of cationic residues in formation and in vitro activity of DNA polyplexes (Corrigendum)
  Hum Gene Ther 1999 Plank C, Tang MX, Wolfe AR, Szoka FC
• Branched cationic peptides for gene delivery: role of type and number of cationic residues in formation and in vitro activity of DNA polyplexes.
  Human gene therapy 1999 Plank C, Tang MX, Wolfe AR, Szoka FC
• Synthesis and characterization of bay region halohydrins derived from Benzo[a]pyrene diol epoxide and their role as intermediates in halide-catalyzed cis adduct formation.
  Chemical research in toxicology 1998 Song Q, Negrete GR, Wolfe AR, Wang K, Meehan T
• Benzo[a]pyrene diol epoxide-DNA cis adduct formation through a trans chlorohydrin intermediate.
  Proceedings of the National Academy of Sciences of the United States of America 1997 Meehan T, Wolfe AR, Negrete GR, Song Q
• The effect of temperature on the stereochemistry of adducts and hydrolysis products derived from anti-benzo[a]pyrene diol epoxide in the presence and absence of halide ions
  Polycyclic Aromatic Compounds 1996 Alan R Wolfe, Qi Song, Thomas Meehan
• The effect of sodium ion concentration on intrastrand base-pairing in single-stranded DNA.
  Nucleic acids research 1994 Wolfe AR, Meehan T
• Halide-catalyzed cis product formation in the hydrolysis of anti-benzo[a]pyrene diol epoxide and its alkylation of poly(A).
  Chemical research in toxicology 1994 Wolfe AR, Meehan T
• Pyrene-modified oligodeoxynucleotides - enhanced duplex binding and stability towards exonuclease degradation in vitro
  Journal of Cellular Biochemistry 1993 Shibata Y, Mann JS, Wolfe AR, Meehan T
• The formation of covalent adducts between benzo[a]pyrenediol epoxide and RNA: structural analysis by mass spectrometry.
  Biochemistry 1990 Yamamoto J, Subramaniam R, Wolfe AR, Meehan T
• Equilibrium binding of benzo[a]pyrene tetrol to synthetic polynucleotides: sequence selectivity, thermodynamic properties, and ionic strength dependence.
  Biochemistry 1988 Shimer GH, Wolfe AR, Meehan T
• Saturated amines and diamines as substrates which inhibit beef liver mitochondrial monoamine oxidase.
  Journal of bioenergetics and biomembranes 1984 Von Korff RW, Wolfe AR
• Some Generally Unrecognized Properties of Purified Monoamine Oxidase B (Beef Liver)
  Journal of Pharmacy and Pharmacology 1984 Von Korff RW, Wolfe AR
• Reversible inactivation of monoamine oxidase by one-electron reduction of the flavin
  39th Fall Scientific Meeting, Midland (Michigan) Section of the American Chemical Society 1983 Von Korff RW, Wolfe AR
• The effect of superoxide dismutase on phenazine methosulfate inhibition of monoamine oxidase
  Developments in Biochemistry 1982 Von Korff RW, Wolfe AR
• Function and Regulation of Monoamine Enzymes: Basic and Clinical Aspects (E. Usdin, N. Weiner, M. B. H. Youdim, Eds.)
  Anomalies in MAO assays using delta A249 and delta O measurements with benzylamine as substrate 1981 Von Korff RW, Wolfe AR